Medium Chain Triglycerides

About

What it is and where it shows up.

Medium chain triglycerides (MCTs) are triglycerides composed predominantly of caprylic (C8) and capric (C10) saturated fatty acids esterified to a glycerol backbone, occurring naturally in coconut oil, palm kernel oil, and milk fat. Unlike long-chain triglycerides, MCTs are rapidly absorbed from the small intestine directly into the portal bloodstream and preferentially oxidized in the liver to yield an immediate energy source and ketone bodies, making them widely used in clinical nutrition, infant formulas, dietary supplements, and functional foods.

Safety summary

The regulatory and scientific consensus.

MCTs have no identified carcinogenic or mutagenic potential, and human dietary consumption up to 1 g/kg body weight per day has been confirmed as safe across multiple clinical trials. High-dose intake may cause gastrointestinal adverse effects including nausea, vomiting, diarrhea, and abdominal cramping; a 2021 meta-analysis found MCT oil causes a small but statistically significant increase in serum triglycerides. Exclusive reliance on MCT as the sole dietary fat source may lead to essential fatty acid deficiency, and their use in healthy infants without specific medical indications is not recommended.

Regulatory landscape

What food-safety regulators have decided.

Jurisdiction	Status	Note
EFSA (European Food Safety Authority) (European Union)	Approved	Primarily authorized for use in Foods for Special Medical Purposes (FSMPs) under Regulation (EU) No 609/2013 for conditions including fat malabsorption, ketogenic dietary therapy for refractory epilepsy, and inherited disorders of long-chain fatty-acid oxidation. EFSA reviewed health claims related to MCTs and body weight in 2011 (EFSA Journal 2011;9(6):2240). No dedicated E-number; not listed as a standard EU food additive.source
MHLW (Ministry of Health, Labour and Welfare) (Japan)	Approved	MCT products are approved and distributed as Foods for Specified Health Uses (FOSHU) and Foods with Function Claims (FFC) targeting healthy adults and older populations. Japan was the first country to market an MCT-based designer lipid cooking oil under the brand name Resetta (2000). Medium-chain fatty acids are not included in the government-prescribed list of nutrients eligible for nutrient function claims.source
FDA (Food and Drug Administration) (United States)	Approved	GRAS status confirmed via multiple notifications: GRN No. 449 covers use in a variety of food categories (FDA issued 'no questions' letter); GRN No. 1049 covers use in infant formula products. Use levels are self-limiting due to GI tolerability thresholds. MCTs are also widely marketed as dietary supplements and medical foods.source

Who should approach with care

Whose guidance would steer them away.

Infants — MCTs are not recommended as an additive to standard formulas for healthy infants; their use should be confined to strictly specified medical indications, as noted by pediatric clinical guidance and the PMC review on MCT formulas in paediatric practice.

Liver Disease — Medium-chain fatty acids bypass lymphatic transport and are carried directly via the hepatic portal vein to the liver for oxidation, imposing a direct metabolic load that may be hazardous in patients with compromised hepatic function.

Ibs — High-dose MCT oil intake is associated with significant gastrointestinal adverse events—including vomiting, diarrhea, and abdominal cramping in up to 85% of subjects in clinical studies—which can exacerbate symptoms in individuals with irritable bowel syndrome.

Ibd — The high incidence of GI adverse events (vomiting, diarrhea, abdominal cramping) observed with MCT oil supplementation in clinical trials warrants caution in individuals with inflammatory bowel disease, for whom GI tolerability is already compromised.

Research citations

The sources behind this verdict.

1FDA. GRAS Notice No. 1049: Medium-chain triacylglycerols (Infant Formula). fda.gov
2FDA. GRAS Notice No. 449: Medium Chain Triglycerides. hfpappexternal.fda.gov
3PubMed. Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context—A Concise Review, 2025. pmc.ncbi.nlm.nih.gov
4PubMed. Triglycerides of medium-chain fatty acids: a concise review, 2022. pubmed.ncbi.nlm.nih.gov
5PubMed. Medium-Chain Triglyceride Oil and Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Trials, 2021. pubmed.ncbi.nlm.nih.gov
6EFSA. Scientific Opinion on the substantiation of health claims related to medium-chain triglycerides and reduction in body weight (ID 643, 677, 1614) pursuant to Article 13(1) of Regulation (EC) No 1924/2006, 2011. efsa.europa.eu

Independently researched7 citations